– Notable launches The ANSWer Study, it’s new observational clinical trial for patients with blood cancer and is currently enrolling patients.
– The primary assessment is to establish a tumor registry with annotated clinical outcomes.
Notable, a San Francisco, CA-based company redefining cancer treatment with a clinically validated platform that rapidly advances drug development, is currently enrolling patients in its new observational clinical trial. The clinical trial will take place at multiple sites across the country and will focus on hematologic malignancies (blood cancers).
Clinical Trial Background & Overview
Notable’s prospective, multicenter, observational study will collect de-identified biospecimens with matched clinical data from up to 1,000 participants from clinical networks in the United States and Canada. Relevant de-identified clinical information and medical data will be collected from participants upon study entry and during subsequent visits for up to one year. Hematologic malignancies that will be studied in this trial include: Acute Myelogenous Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia and Myeloproliferative Neoplasm, to name a few.
The primary assessment is to establish a tumor registry with annotated clinical outcomes. Exploratory assessments include correlation of ex vivo functional testing results with clinical outcomes, as well as identification of potential biomarkers that correlate clinical responses with genotype and/or phenotype.
Notable’s AI-Based Platform
Notable’s automated AI-based platform is built to help predict patient responses to therapies in as little as 7 days. As a precision oncology company, Notable seeks to match patients with effective therapies, and accelerate the drug development process for novel therapeutics. The goal is to help patients and their physicians make better informed decisions about which treatments and clinical trials might be most effective.
A feasibility study conducted at the Stanford University School of Medicine demonstrated that Notable achieved an 84 percent overall accuracy rate in retrospectively predicting patient therapeutic responses. The most recent data from this collaboration was presented at the American Society of Hematology Society Annual Meeting in December of 2019.
Why It Matters
“The observational clinical trial that we’re kicking off will give us the opportunity to test more patients than ever before, allowing us to continue increasing the platform’s predictive value,” said De Silva. “Notable’s platform improves with every patient and The ANSWer Study brings our technology one step closer to being used as a tool to help physicians and patients make complex treatment decisions in the clinic which is our ultimate goal,” said Matt De Silva, Notable’s founder, and CEO.
For more details on Notable’s IRB (Institutional Review Board) approved clinical trial, please visit: https://clinicaltrials.gov/